Creatine and Alzheimer's: What Research Is Investigating

Search “creatine Alzheimer’s” and you’ll find a lot of excitement and a lot of overstatement. The brain runs on energy, creatine is central to how cells recycle energy, and that has made creatine an interesting molecule for scientists who study the aging brain. But interest is not the same as evidence. This page walks through what creatine brain disease research has actually tested — past tense, as described in the studies themselves — and where it honestly stands.

Why researchers got interested in creatine and dementia

The starting point is mechanism, not outcome. The brain is a major energy consumer, brain creatine tends to decline with age, and creatine helps cells regenerate ATP — their energy currency — during periods of high demand. Reviews note that any cognitive signals tend to cluster in people with lower baseline creatine or under conditions of metabolic stress. That’s a reasonable hypothesis worth testing. It is also exactly that: a hypothesis. A plausible mechanism does not establish that supplementing changes the course of a brain disease.

What the Alzheimer’s research has actually tested

The headline study people cite is a 2025 pilot. It gave 20 people (ages 60–90) with Alzheimer’s disease 20 g/day of creatine for 8 weeks; 19 finished. Brain total creatine rose about 11%, and several cognitive composites moved in a positive direction.

Here’s the part the headlines skip: this was a single-arm feasibility pilot with no placebo group and only 20 participants. Without a control group, apparent cognitive improvements cannot be attributed to creatine — practice effects from repeated testing, expectancy, and regression to the mean can all produce the same pattern. The study’s own authors framed it as establishing feasibility and brain-creatine uptake, not efficacy, and called for placebo-controlled trials.

The neuroprotection story: big trials, negative results

“Creatine neuroprotection” gets repeated online as if it were settled. The most rigorous tests in actual neurodegenerative disease point the other way. A large Parkinson’s disease trial randomized 1,741 patients to creatine 10 g/day or placebo for up to five years and found no difference in clinical progression. A Huntington’s disease trial randomized 553 people and was halted early for futility — an interim analysis indicated, with high confidence, no benefit.

These trials tested creatine as a disease-modifying neuroprotectant in specific diseases. They don’t speak directly to everyday memory in healthy aging, but they clearly refute broad claims that creatine slows neurodegeneration.

What about memory and cognition in healthy older adults?

This is a separate question from disease, and it’s also unsettled. Meta-analyses have reported a small overall memory signal in healthy adults, with a larger but fragile effect in older subgroups that rests on only a handful of small, highly variable trials. Other domains — global cognition and executive function — show no reliable effect. Crucially, the European Food Safety Authority reviewed this evidence in 2024 and concluded that a cause-and-effect relationship between creatine and improved cognitive function has not been established. A dedicated 2025 review of the aging brain found only “limited evidence,” drawn largely from cross-sectional data and just two supplementation trials.

So we won’t claim creatine sharpens memory or focus. The brain-energy mechanism is real; a dependable cognitive benefit in healthy people is not established.

What is well-supported

To keep this honest in both directions: creatine monohydrate has a strong long-term safety record in healthy adults with normal kidney function, with clinical data up to 30 g/day for as long as five years without adverse effects. And for older adults, the most consistent benefit is physical — when paired with resistance training, creatine has been shown across many trials to support strength gains (about +2 kg on one-rep-max in adults 55+). Those are not brain claims. People who are pregnant, nursing, or have kidney conditions should consult a doctor before supplementing.

The bottom line

Creatine and Alzheimer’s research is an open, early-stage field. A small pilot showed creatine can reach the brain and was feasible in Alzheimer’s patients; rigorous neuroprotection trials in other brain diseases were negative; and the cognition evidence in healthy aging is mixed and officially unproven. None of that is a reason to take creatine for a disease — please don’t. Vantra is simply a clean, studied 5 g/day of creatine monohydrate (Creapure), split between a citrus Dawn scoop in the morning and a wild-berry Dusk scoop at night. We think the research is fascinating, and we’d rather report it accurately than oversell it.